Clinical Psychopharmacology Decision Making

Patient Assessment and Treatment Planning

The American Academy of Child and Adolescent Psychiatry recommends a comprehensive psychiatric and medical evaluation to identify pharmacological targets, development of a specific treatment plan, and systematic assessment of response using standardized tools before making any medication changes 1, 2
Complete psychiatric interviews with both patient and family are necessary to identify symptoms requiring pharmacological intervention versus psychosocial treatment 1
A biopsychosocial diagnostic formulation is used to guide treatment selection, considering the patient's history, symptoms, and previous treatment records 1, 3

For ADHD, medication management is the first-line treatment, with combined behavioral treatment added for complex cases, as recommended by the American Academy of Child and Adolescent Psychiatry 3
For OCD, cognitive-behavioral therapy or combined treatment is the optimal first option, according to the American Academy of Child and Adolescent Psychiatry 3
For moderate-to-severe depression, combination therapy or medication management is preferred over psychotherapy alone, as shown in the Treatment of Adolescent Depression Study 3
Atypical antipsychotics are first-line treatment for schizophrenia due to efficacy and side-effect profile, with clozapine reserved for treatment-refractory cases, as recommended by the American Academy of Child and Adolescent Psychiatry 4

The American Academy of Child and Adolescent Psychiatry recommends starting with low doses and titrating gradually, with large initial doses not hastening recovery and typically causing excessive side effects 4, 6
Antipsychotic therapy should be implemented for no less than 4-6 weeks at adequate dosages before determining efficacy, as recommended by the American Academy of Child and Adolescent Psychiatry 4, 2, 6
Medication adherence should be verified through pill counts, pharmacy records, or blood levels before concluding treatment failure, as recommended by the American Academy of Child and Adolescent Psychiatry 2

Metformin should be offered concomitantly when starting olanzapine or clozapine to attenuate weight gain, as recommended by the American Academy of Child and Adolescent Psychiatry 2
Fasting glucose, weight, BMI, waist circumference, and blood pressure should be monitored regularly to assess metabolic risk, as recommended by the American Academy of Child and Adolescent Psychiatry 2

Psychosocial interventions should be initiated at the beginning of acute treatment to address inadequate supervision of medication adherence or parental lack of understanding of target symptoms, as recommended by the American Academy of Child and Adolescent Psychiatry 3, 2
Medication-only approaches should not be used, as psychosocial interventions are mandatory components of the treatment plan, as recommended by the American Academy of Child and Adolescent Psychiatry 2
Regular monitoring visits should be scheduled to enhance patient and family confidence in treatment and to allow responders to consolidate gains and achieve remission or recovery, as recommended by the American Academy of Child and Adolescent Psychiatry 1, 3